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Abstract: (1) Background: We aimed to examine if 25-hydroxyvitamin D (25(OH)D) was related to
the peripheral immunological and inflammatory signature both at birth, and in newly diagnosed
patients with childhood type 1 diabetes (T1D) and their healthy controls; (2) Methods: The birth
cohort consisted of 470 patients and 500 healthy controls. Dried blood samples were collected from
the neonates in the period 1981–1999. The newly diagnosed cohort consisted of 460 patients and
453 siblings. Serum samples were collected in the period 1997–2005. A variety of peripheral immune
mediators were measured and compared to total 25(OH)D levels (25(OH)D2 + 25(OH)D3). For each
immune mediator, the relative change (RC) in the mean level was modeled by robust log-normal
regression and correction for multiple testing was performed; (3) Results: Two associations were
identified; there was a negative association between 25(OH)D (10 nmol/L increase) and leptin
(RC (95% confidence interval (CI)), 0.98 (0.96; 1.00)), and a positive association between 25(OH)D
(10 nmol/L increase) and the chemokine, chemokine (c-x-c motif) ligand (CXCL) 8 (RC (95% CI),
1.07 (1.01; 1.13)); (4) Conclusion: CXCL8 and leptin have significant associations with levels of
25(OH)D in the newly diagnosed cohort. These results do not indicate a strong influence of 25(OH)D
on the peripheral immunological or inflammatory signature.
Keywords: Diabetes Mellitus, Type 1; vitamin D; Cytokines/immunology; TREM1, human;
C-reactive protein; mannose-binding lectin; Infant, Newborn; Child; Adolescent
1. Introduction
Type 1 diabetes (T1D) is an endocrine disease that results from autoimmune destruction of
the pancreatic insulin-producing β-cells, leading to a loss of insulin secretion and symptomatic
hyperglycemia. Changes in the complex interplay between genetic, epigenetic, and environmental
factors are thought to be involved in T1D etiopathogenesis [1–3].
Vitamin D is in the spotlight, as many in vitro and animal studies indicate that vitamin D has
anti-inflammatory activity and may also prevent or halt the destruction of β-cells [4,5]. Findings from
epidemiological studies focusing on the association between vitamin D and T1D, both in early life and
around time of diagnosis, are inconsistent [6,7]. However, to our knowledge, no large-scale studies have
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yet examined if there are any associations of 25-hydroxyvitamin D (25(OH)D) with peripheral immune
mediators in cohorts of patients with childhood T1D and healthy controls. Therefore, we aimed to
examine if 25(OH)D was associated with a wide range of peripheral immune mediators at two different
time-windows, namely (1) at birth in patients who subsequently developed childhood T1D and their
healthy controls and (2) in newly diagnosed patients with childhood T1D, and their healthy siblings.
2. Materials and Methods
2.1. Study Design, Sample Population, Data Sources and Variables
We conducted two separate case-control studies—both study samples are described extensively
elsewhere including coding of covariates [7–10].
2.1.1. The Birth Cohort Samples
Blood sampling (dried blood spots (DBS)) was performed within a week following birth during
the years 1981 to 1999. For each identified clinical case (a neonate who subsequently develops
T1D before the age of 18 years) one control was selected based on having measurements on both
peripheral immune mediators and 25(OH)D. Clinical cases were identified from the Danish Patient
Register and further validated against the Danish Registry of Childhood and Adolescent Diabetes
(DanDiabKids) [11]. Our random sample of clinical cases and controls are based on a sub-sample from
a population-based case-control study comprised of 2086 clinical cases and 4172 controls [12]. In the
original study the following inclusion criteria were: (1) born between 1981 and 2002 (<0.5% of the
individuals were born between 2000 and 2002); (2) diagnosed with T1D between 1 January 1981 and
1 May 2004; (3) had an available DBS card in the Danish Newborn Screening Biobank (DNSB). Exclusion
criteria were: (1) additionally diagnosed with another diabetes type; (2) insufficient biological material
on the DBS card; (3) not a singleton (3% of the cohort). Controls were selected by collecting the DBS
card next to the case’s card in the DNSB, hereby matching on date of birth.
Since 1981 the DBS have been stored at −20 ◦C/−4 ◦F in the DNSB and this biobank comprises
almost 100% of the Danish population born since 1982 [13].
2.1.2. The Newly Diagnosed Cohort Samples
A random sample of 500 clinical cases was collected from a biobank linked to the DanDiabKids.
Blood samples were taken less than three months after the onset of T1D during the years 1997 to 2005.
The onset date was defined as the date of the first insulin injection. The control group comprised a
random sample of 500 siblings selected from an eligible sample of approximately 2000 siblings with
blood samples stored in the biobank and a sibling diagnosed with T1D. The chosen control sample
was independent of participation of a sibling with T1D in the study. Randomization aimed at covering
all sample months (January 1997 to December 2005). A last inclusion criterion was that all individuals
had to be between 0 to 18 years of age at time of blood sampling.
Serum samples from the DanDiabKids were stored at −80 ◦C/−112 ◦F during the entire study
period from 1997 to 2005.
2.2. Outcome Assessment
2.2.1. Assessment of Peripheral Immune Mediators on Dried Blood Spots
Multiplexed sandwich immunoassays and the flowmetric Luminex xMAP® technology were
used to quantify the following cytokines: interleukin (IL)-1β, IL-4, IL-6, chemokine (c-x-c motif)
ligand 8 (CXCL8), IL-10, IL-12 (p70), interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα),
transforming growth factor beta 1 (active form) (TGFβ), leptin, and adiponectin. In addition, we also
quantified c-reactive protein (CRP), mannose-binding lectin (MBL) and soluble triggering receptor
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expressed on myeloid cells-1 (sTREM-1) [14]. In all assays, matched pairs were run together to avoid
batch effects/interassay variation [15]. Biomarker analyses are described in detail elsewhere [14].
Quality control of the analysis were made using mouse IL-6 as an internal analyte added
to the extraction buffer to detect pipetting errors, and biotinylated beads to detect signal errors
(more thoroughly described in Skogstrand et al. [16]). Calibration curves were used on each plate
together with one high and two low controls. Samples, calibrators, and controls were analyzed in duplicate.
2.2.2. Assessment of Peripheral Immune Mediators in Serum
The serum samples were analyzed using the commercially available high-capacity Luminex
xMAP technology combined with a 15-plex and 3-plex developed in-house for the simultaneous
determination of 18 biomarkers, as described in Skogstrand et al. [14]. The secreted immune and
inflammatory mediators measured were: IL-1β, IL-4, CXCL8, IL-10, IL-12 (p70), IL-18, IFNγ, TNFα,
TGFβ, CCL2, CCL3, CCL4, CCL5, leptin, adiponectin, CRP, MBL and sTREM-1. The coefficient of
variation (CV), as described elsewhere [14], was analysed for each of the assays.
2.3. Exposure Assessment
2.3.1. Assessment of 25(OH)D on Dried Blood Spots
In short, 25(OH)D status was assessed by measuring 25(OH)D2 and 25(OH)D3 in 3.2 mm samples
(also called punches) taken from DBS cards. Sample preparation and analysis was performed using
liquid chromatography–mass spectrometry (LC-MS) according to a modified method [17], described
in detail elsewhere [9].
The lower limit of quantification (LLOQ) was 4 nmol/L for 25(OH)D3 and 3 nmol/L for 25(OH)D2.
The 25(OH)D levels from the DBS are full blood concentrations. Most 25(OH)D molecules in the
bloodstream are protein bound and to approximate and report sera concentrations we corrected the
original levels using the formula: serum 25(OH)D = full blood 25(OH)D × (1/(1 − 0.61)), where 0.61 is
the haematocrit fraction for capillary blood [18].
2.3.2. Assessment of 25(OH)D in Serum
Vitamin D status was measured as serum 25(OH)D by high-performance liquid chromatography
(HPLC) [19]. Detection limit for 25(OH)D was 9.5 nmol/L, with a CV of 8%.
2.4. Statistical Analysis
For each peripheral immune mediator the relative change (RC) in the mean level by 10 nmol/L
increase in total 25(OH)D (equivalent to 25(OH)D2 + 25(OH)D3) was modeled by a robust log-normal
model regression, which takes into account: (1) that measurements are potentially both left and right
censored; and (2) correlation within assay. To account for correlation within cluster inference was
based on a working independence generalized estimation equation (GEE) approach. For the birth
cohort the clusters are equivalent to assay. For the newly diagnosed cohort, the cluster was equivalent
to family/sibling ID.
For the birth cohort, the following risk factors are included in the model: 25(OH) levels, sex, case
status (T1D or control), gestational age, mothers age, birth weight, season and calendar year group.
For the newly diagnosed cohort the following risk factors are included in the model: 25(OH) level, sex,
case status (T1D or sibling), age at blood sampling, season and calendar year group. The coding of
these variables is presented in Table 1.
Simultaneous evaluation of risk factors on all peripheral immune mediators was done using the
model stacking approach detailed in Pipper et al. [20]. Subsequent adjustment for multiple testing and
familywise 95% confidence bands are calculated using the single step procedure by Hothorn et al. [21].
Likelihood ratio estimates of mean ratios and accompanying confidence limits are calculated on a log
scale and transformed back to the original scale.
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Table 1. Descriptive characteristics of the two pediatric cohorts.
Variables




(n = 470) (n = 500) (n = 460) (n = 453)
Basic characteristics
Sex
Female, n/% of total 231/49.1 231/46.2 0.39 218/47.4 198/43.7 0.29
Male, n/% of total 239/50.9 269/53.8 242/52.6 255/56.3
Age at onset 2
Median/ 8.2/ 10.4/ 10.3/ 0.41
Q1–Q3 3, years 4.8–11.0 7.4–12.5 7.8–12.8
Pregnancy and birth
Gestational age
Median/Q1–Q3, weeks 40/39–41 40/39–40 0.58
Birth weight, n/% of total
<2500 g 19/4.0 30/6.0
2500–4499 g 441/93.8 460/92.0 0.38
>4500 g 10/2.1 10/2.0
Birth length
Median/Q1–Q3, cm 52/51–53 52/50–53 0.37
Mother’s age at child’s birth
Median/Q1–Q3, years 28/25–31 28/25–31 0.84
Season and time period of blood sampling
Season, n/% of total 4
Winter 104/22.1 106/21.2 117/25.4 118/26.0
Spring 112/23.8 125/25.0 0.49 115/25.0 116/25.6 0.11
Summer 113/24.0 137/27.4 105/22.8 126/27.8
Autumn 141/30.0 132/26.4 123/26.7 93/20.5
Time period, n/% of total 5
1. 1981–1987 or 1997–1999 177/37.7 171/34.2 143/31.1 210/46.4
2. 1987–1991 or 2000–2002 152/32.3 177/35.4 0.48 94/20.4 45/10.0 <0.0001
3. 1991–1999 or 2003–2005 141/30.0 152/30.4 223/48.5 198/43.7
1 When comparing groups, the statistical tests used are chi-square test for categorical, and Mann-Whitney U for
numerical variables; 2 For the newly diagnosed cohort this equals the age at blood sampling for both patients
(within 3 months after onset of childhood T1D) and siblings; 3 First and third quartile; 4 Winter (December
through February), spring (March through May), summer (June through August) and autumn (September through
November); 5 The first time period represents the birth cohort and the second represents the newly diagnosed
cohort. T1D, childhood type 1 diabetes.
Overall functional misspecification by including 25(OH)D as a trend (linear variable) was assessed
by a lack-of-fit test. Specifically, we included a quadratic term of 25(OH)D and tested its significance
by a robust Wald test.
All analyses are made using the statistical software package R version 3.2.0 (the R foundation for
statistical programming, Vienna, Austria) and the add-on packages survival, ggplot2, and multcomp.
2.5. Ethics
Both studies were performed in accordance with the Helsinki II Declaration. Furthermore, both
studies were approved by the Danish Ethical Committee (H-4-2013-049 and H-KA-20070009). All of
the patients and their parents or guardians gave informed consent.
3. Results
3.1. Basic Characteristics for both Cohorts are Presented in Table 1
The birth cohort contains 970 individuals with a complete set of covariates (470 patients and
500 controls). In the birth cohort, the median/first and third quartile (Q1–Q3) 25(OH)D level
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was 26.3/17.1–38.8 nmol/L for patients and 25.7/17.0–37.8 for controls. The newly diagnosed
cohort contains 913 individuals with a complete set of covariates (460 patients and 453 controls).
In the newly diagnosed cohort the median/Q1–Q3 25(OH)D level was 62.0/40.1–95.5 for patients
and 57.9/38.0–89.0 nmol/L for controls. It is noteworthy to mention that we have already shown
that 25(OH)D levels are not associated with later risk of childhood T1D in the birth cohort and
levels between newly diagnosed patients with childhood T1D and their healthy siblings do not differ
either [7,9]. Levels of the peripheral immune mediators are presented in Table 2.
Table 2. Absolute levels of peripheral immune mediators stratified by cohort and case status.
Peripheral Immune Mediators
Birth Cohort Newly Diagnosed Cohort
Patient Control Patient Sibling
(n = 470) (n = 500) (n = 460) (n = 453)
IL-1β
Median/Q1–Q3, ng/L 45.1/22.8–80.0 40.3/21.3–77.1 23.0/10.3–71.3 18.2/8.1–58.9
IL-4
Median/Q1–Q3, ng/L 20.1/12.4–31.0 20.7/12.8–31.7 9.5/2.0–21.7 8.4/2.0–17.2
IL-6
Median/Q1–Q3, ng/L 33.7/21.3–60.0 37.5/22.1–65.5
CXCL8
Median/Q1–Q3, ng/L 85.2/58.7–138.4 89.8/63.7–138.3 2517.3/433.5–4914.1 1923.5/305.6–4593.0
IL-10
Median/Q1–Q3, ng/L 242.9/64.5–793.8 245.3/72.5–721.2 47.2/25.8–92.8 44.2/20.9–79.7
IL-12
Median/Q1–Q3, ng/L 94.8/56.5–147.8 92.9/52.5–146.5 27.5/12.3–56.1 21.7/10.2–45.6
IL-18
Median/Q1–Q3, ng/L 183.8/119.8–285.9 142.4/104.0–212.0
IFNγ
Median/Q1–Q3, ng/L 34.7/17.1–61.9 39.8/19.8–65.2 106.1/57.9–211.3 93.9/50.1–177.3
TNFα
Median/Q1–Q3, ng/L 43.7/25.8–67.7 42.7/26.1–68.0 69.4/26.3–134.8 65.0/16.1–131.9
TGFβ
Median/Q1–Q3, ng/L 927.2/603.5–1385.3 1006.6/687.7–1414.9 233.6/142.6–341.3 166.9/104.2–256.4
Leptin
Median/Q1–Q3, ng/L 3079/1953–4678 3143/2022–4588 368.1/174.5–772.1 430.6/192.1–930.7
Adiponectin
Median/Q1–Q3, mg/L 13.4/9.3–20.1 13.3/9.1–19.8 14.9/11.0–19.5 14.4/11.1–19.7
CRP
Median/Q1–Q3, mg/L 0.9/0.3–2.0 1.0/0.4–2.0 0.04/0.01–0.16 0.02/0.01–0.09
MBL
Median/Q1–Q3, mg/L 0.6/0.2–1.0 0.5/0.18–1.1 1.9/0.7–3.3 1.2/0.5–2.3
sTREM-1
Median/Q1–Q3, ng/L 2868.5/1533.4–4930.9 2693.5/1524.9–5180.5 3368/244–16411 1085/244–9442
CCL2
Median/Q1–Q3, ng/L 303.3/174.3–725.6 261.1/146.1–683.5
CCL3
Median/Q1–Q3, ng/L 234.5/120.4–520.3 202.2/107.7–517.7
CCL4
Median/Q1–Q3, ng/L 330.7/187.1–704.5 320.1/186.8–739.6
CCL5
Median/Q1–Q3, ng/mL 10.8/6.7–29.2 13.7/7.2–36.3
IL, interleukin; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha; TGFβ, transforming growth factor
beta; CRP, c-reactive protein; MBL, mannose-binding lectin; sTREM-1, soluble triggering receptor expressed on
myeloid cells-1, CXCL, chemokine (c-x-c motif) ligand; CCL, chemokine (c-c motif) ligand.
3.2. Association between Peripheral Immune Mediators and 25(OH)D in the Birth Cohort
We were unable to detect any linear association of 25(OH)D on the 14 examined peripheral
immune mediators. The numeric results including a graphical overview (forest plot) are presented in
Figure 1.
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We also examined if non-linear associations existed between 25(OH)D and the peripheral immune
mediators in the birth cohort, but found no sign of such associations (p = 0.25).
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Figure 1. Relative change in mean levels of immune mediators with 95% confidence bands by
10 nmol/L increase in 25(OH)D levels in the birth cohort—results from the full adjusted model.
IL, interleukin; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha; TGFβ, transforming
growth factor beta; CRP, c-reactive protein; MBL, mannose-binding lectin; sTREM-1, soluble triggering
receptor expressed on myeloid cells-1; CXCL, chemokine (c-x-c motif) ligand.
3.3. Association between Peripheral Immune Mediators and 25(OH)D in the Newly Diagnosed Cohort
We only found a statistical significant positive association between 25(OH)D (10 nmol/L increase)
and CXCL8 (RC (95% CI), 1.07 (1.01; 1.13), padjusted = 0.02), and a negative association between 25(OH)D
(10 nmol/L increase) and leptin (RC (95% CI), 0.98 (0.96; 1.00), padjusted = 0.01). The other 16 peripheral
immune mediators were not associated with 25(OH)D. The numeric results including a graphical
overview (forest plot) are presented in Figure 2.
A f r the birth cohort, we also examined if a non-linear associations between 25(OH)D and the
peripheral immune mediators existed in the newly diagnosed cohort, but no proof of such associations
were found (p = 0.26).
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4. Discussion
In these two large-scale, case-control studies, 14 peripheral immune mediators were measured in
a birth cohort and 18 peripheral immune mediators were measured in a newly diagnosed childhood
T1D cohort. 25(OH)D levels were compared with these immune and inflammatory factors, and two
peripheral immune mediators, i.e., CXCL8 and leptin, were associated with 25(OH)D in the newly
diagnosed cohort. These results do not indicate a strong role of 25(OH)D as an immune modulator
when using peripheral immune mediators as a proxy for the child’s immunological fingerprint.
We demonstrated that CXCL8 levels in our newly diagnosed cohort rises with 1%–13% for
every 10 nmol/L increase in 25(OH)D. CXCL8, also known as IL-8, is a chemokine which affects
leukocyte migration positively and thereby promotes inflammation [22]. Interestingly, the CXCL8
gene has been shown to be a vitamin D receptor (VDR) binding-site; hence the active form of
vitamin D (1,25(OH)2D) can alter, e.g., up-regulate, its expression, which may help to clear infections
by recruitment of specific immune cells [23,24]. In an in vitro study using hyperinflammatory
macrophages from patients with cystic fibrosis, vitamin metabolites have been shown, in high
concentrations (e.g., 25(OH)D >100 nmol/L), to down-regulate CXCL8 [25]. These discrepancies could
be due to different cell lines used e.g., monocytic leukemia cell line (THP-1) versus hyperinflammatory
macrophages, but may also depend on choice of vitamin D metabolite, vitamin D metabolite
concentration, and cell culture duration [23,25]. Our results reflect an overall systemic in vivo
association of 25(OH)D on CXCL8 levels. The role of CXCL8 in regards to T1D pathogenesis remains to
be examined, but we previously reported no difference in CXCL8 levels between patients and healthy
controls in both these cohorts [26]. Furthermore, no association between 25(OH)D and CXCL8 was
found in the birth cohort.
We also found leptin levels significantly reduced with 0%–4% for every 10 nmol/L increase in
25(OH)D in the newly diagnosed cohort. Leptin is an adipokine, secreted primarily from adipose
tissue. The overall action of leptin in the immune system is to activate leukocytes and mediate
inflammation [27]. In a recent study that utilized the newly diagnosed cohort, we found leptin levels
were 10%–40% lower in patients with childhood T1D compared to their healthy siblings, but this
finding was not mirrored by higher 25(OH)D levels [7,28]. A systematic review and meta-analysis
conducted on adult populations without T1D also found evidence of an inverse relationship between
25(OH)D and leptin, but well-designed clinical trials with vitamin D supplementation of more than
1000 IU/day are needed to confirm such a relationship [29].
The effect sizes of the abovementioned significant associations are both small, and may not
have profound immunological importance. Importantly, we do not find any association between
physiological 25(OH)D levels and well-known Th1, Th2 or Treg cytokines that have been associated
with either β-cell destruction or protection e.g., IL-1β, IFNγ, TNFα, IL-10 and TGFβ [30,31].
This study has a number of strengths. Firstly, the sample size in both cohorts includes over
900 individuals—both cohorts consist of a patient group (childhood T1D) and a healthy control
group (in the newly diagnosed cohorts these healthy controls are a sampling of siblings). Secondly,
both cohorts are population-based and patients with childhood T1D are thoroughly validated and
controls are randomly selected. Thirdly, quantification of both 25(OH)D and a broad spectrum of
peripheral immune mediators, initially measured for testing other hypotheses, gave us the opportunity
to conduct the current study using these unique cohorts. Our study also has some limitations. Firstly,
a single measurement of both 25(OH)D and peripheral immune mediators may not detect long-term
differences or reflect dynamic changes. Secondly, sample storage time may influence assay measures
due to degradation, however calendar year of blood sampling was included in both models to control
for this. Thirdly, one may ask if these measured peripheral immune mediators, in some part, mirror
or affect the tissue-specific immunological micro-milieu in the islet of Langerhans in the pancreas.
Or, it could be the case that we just looking at a more general immunological cross-sectional fingerprint
and its association with 25(OH)D. Either way, we find a very small influence of 25(OH)D on these
peripheral immune mediators.
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5. Conclusions
We have examined a wide range of peripheral immune and inflammatory mediators in both
neonates who subsequently develop childhood T1D, and in a separate cohort of newly diagnosed
patients with childhood T1D. Two immune factors, i.e., CXCL8 and leptin, have significant associations
with levels of 25(OH)D in the newly diagnosed cohort. These results indicate that vitamin D does not
appear to play a major role as an immune-modulator of the peripheral immune system. To further
understand a possible role of vitamin D on the human immune system, studies need to be performed in
more complex systems that include genetics, repeated measures of functional immune cell populations
and gene-immune mediator interactions.
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